BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| 7.394 | |
| 7.394 | |
| - | |
| 7.394 | |
| 7.394 | |
| 3.837-7.824 | |
| 1 530 M | |
| 207 M | |
| 382 M | |
| 1.876 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BioCryst Pharmaceuticals (BCRX) shares soared 25.6% in the last trading session to close at $7.65. The move was backed by solid volume with far more shares changing hands than in a normal session. Thi...
BioCryst Pharmaceuticals, Inc. —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
